Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Venetoclax & AML

Charles Craddock • 17 Apr 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Cusatuzumab Magrolimab Venetoclax

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, touches on the promising data seen in use of venetoclax for the treatment of acute meyloid leukemia (AML), the optimization of this treatment for different patient populations and it’s use in the post-transplant setting. Cusatuzumab and magrolimab are also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals